Giambattista Guaitoli

A homologue of the Parkinson’s disease-associated protein LRRK2 undergoes a monomer-dimer transition during GTP turnover

Egon Deyaert, Lina Wauters, Giambattista Guaitoli et al. · Nature Communications · 2017 · 460 citations · Full text

Structural model of the dimeric Parkinson’s protein LRRK2 reveals a compact architecture involving distant interdomain contacts

Giambattista Guaitoli, Francesco Raimondi, Bernd K. Gilsbach et al. · Proceedings of the National Academy of Sciences · 2016 · 154 citations · Full text

Protein–protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase

Daniela Cardinale, Giambattista Guaitoli, Donatella Tondi et al. · Proceedings of the National Academy of Sciences · 2011 · 103 citations · Full text

Peptide Engineering, Molecular Biology, Peptide Therapeutics +16

Nanobodies as allosteric modulators of Parkinson’s disease–associated LRRK2

Ranjan K. Singh, Ahmed Soliman, Giambattista Guaitoli et al. · Proceedings of the National Academy of Sciences · 2022 · 53 citations · Full text

Allosteric Modulators, Drug Target, Signaling Pathway +16

Auto-regulation of Rab5 GEF activity in Rabex5 by allosteric structural changes, catalytic core dynamics and ubiquitin binding

Janelle Lauer, Sandra Segeletz, Giambattista Guaitoli et al. · eLife · 2019 · 49 citations · Full text

Rab5 Gef, Molecular Biology, Chemical Biology +17